Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
Joseph McLaughlin, Gang Han, Kurt A. Schalper, et al.
JAMA Oncology (2015) Vol. 2, Iss. 1, pp. 46-46
Open Access | Times Cited: 765

Showing 1-25 of 765 citing articles:

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al.
Breast Care (2016) Vol. 11, Iss. 6, pp. 385-390
Open Access | Times Cited: 30388
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, et al.
The Lancet (2015) Vol. 387, Iss. 10027, pp. 1540-1550
Closed Access | Times Cited: 6056
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan, Mark Yarchoan, Elizabeth M. Jaffee, et al.
Annals of Oncology (2018) Vol. 30, Iss. 1, pp. 44-56
Open Access | Times Cited: 2258
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma, Rafael Santana-Dávila, Julian R. Molina
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 8, pp. 1623-1640
Closed Access | Times Cited: 1696
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino, Nikhil H. Ramaiya, Hiroto Hatabu, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 11, pp. 655-668
Open Access | Times Cited: 908
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge, et al.
Nature Medicine (2018) Vol. 24, Iss. 12, pp. 1852-1858
Closed Access | Times Cited: 607
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia‐Wei Li, Seung-Oe Lim, Ezra M. Chung, et al.
Cancer Cell (2018) Vol. 33, Iss. 2, pp. 187-201.e10
Open Access | Times Cited: 471
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jian-Ming Xu, Yun Zhang, Ru Jia, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 2, pp. 515-523
Open Access | Times Cited: 435
PD-L1 Expression in Lung Cancer
Hui Yu, Theresa A. Boyle, Caicun Zhou, et al.
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 7, pp. 964-975
Open Access | Times Cited: 418
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
Anna-Larissa N. Niemeijer, David Leung, Marc C. Huisman, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 418
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini, Daniela Massi, Mario Mandalà
Critical Reviews in Oncology/Hematology (2016) Vol. 100, pp. 88-98
Closed Access | Times Cited: 343
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube, Jérôme Galon, Lynette M. Sholl, et al.
Modern Pathology (2017) Vol. 31, Iss. 2, pp. 214-234
Open Access | Times Cited: 325
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
Aaron S. Mansfield, MC Aubry, Justin C. Moser, et al.
Annals of Oncology (2016) Vol. 27, Iss. 10, pp. 1953-1958
Open Access | Times Cited: 314
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
M. Ratcliffe, Alan Sharpe, Anita Midha, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 14, pp. 3585-3591
Open Access | Times Cited: 285
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Jiao Hu, Anze Yu, Belaydi Othmane, et al.
Theranostics (2021) Vol. 11, Iss. 7, pp. 3089-3108
Open Access | Times Cited: 276
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert S. Brody, Yiduo Zhang, Marc Ballas, et al.
Lung Cancer (2017) Vol. 112, pp. 200-215
Open Access | Times Cited: 275
PD-L1
Anthousa Kythreotou, Abdul Siddique, Francesco Mauri, et al.
Journal of Clinical Pathology (2017) Vol. 71, Iss. 3, pp. 189-194
Open Access | Times Cited: 272
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Sarah Derks, Xiaoyun Liao, Anna Maria Chiaravalli, et al.
Oncotarget (2016) Vol. 7, Iss. 22, pp. 32925-32932
Open Access | Times Cited: 264
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy
Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 970-977
Open Access | Times Cited: 263
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Sylvie Lantuéjoul, Ming‐Sound Tsao, Wendy A. Cooper, et al.
Journal of Thoracic Oncology (2019) Vol. 15, Iss. 4, pp. 499-519
Open Access | Times Cited: 262
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes, Alexios Matikas, Jonas Bergh, et al.
Oncogene (2018) Vol. 37, Iss. 34, pp. 4639-4661
Open Access | Times Cited: 252
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Daixi Ren, Yuze Hua, Boyao Yu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 249
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 7, pp. 529-540
Closed Access | Times Cited: 239
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
Adrian G. Sacher, Leena Gandhi
JAMA Oncology (2016) Vol. 2, Iss. 9, pp. 1217-1217
Closed Access | Times Cited: 233
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Marius Ilié, Véronique Hofman, Manfred Dietel, et al.
Virchows Archiv (2016) Vol. 468, Iss. 5, pp. 511-525
Closed Access | Times Cited: 232
Page 1 - Next Page

Scroll to top